{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Prednisolone&page=2", "query": { "intervention": "Placebo Prednisolone", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Prednisolone&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T10:43:03.604Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00808210", "title": "A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2009-03-05", "completion_date": "2012-11-14", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Murrieta, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00808210" }, { "nct_id": "NCT07623668", "title": "Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Optic Neuritis" ], "interventions": [ { "name": "Privosegtor", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Oculis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 210, "start_date": "2026-05-28", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 4, "location_summary": "Livonia, Michigan • Charleston, South Carolina • Dallas, Texas + 1 more", "locations": [ { "city": "Livonia", "state": "Michigan" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07623668" }, { "nct_id": "NCT04738318", "title": "Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Elbow Fracture" ], "interventions": [ { "name": "Glucocorticoids", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-06-16", "completion_date": "2023-03-10", "has_results": true, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04738318" }, { "nct_id": "NCT04372615", "title": "The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Encephalitis", "Encephalitis" ], "interventions": [ { "name": "Inebilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 116, "start_date": "2022-03-30", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04372615" }, { "nct_id": "NCT06729606", "title": "Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "Aviptadil", "type": "BIOLOGICAL" }, { "name": "Aviptadil Placebo", "type": "BIOLOGICAL" }, { "name": "Corticosteroid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 471, "start_date": "2021-04-20", "completion_date": "2022-11-20", "has_results": true, "last_update_posted_date": "2025-10-09", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 40, "location_summary": "Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06729606" }, { "nct_id": "NCT06952803", "title": "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone + Prednisolone/Prednisone", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 700, "start_date": "2025-08-06", "completion_date": "2036-04-30", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952803" }, { "nct_id": "NCT00915473", "title": "Greater Occipital Nerve Block for Migraine Prophylaxis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine Headache" ], "interventions": [ { "name": "bupivicaine", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "lidocaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 70, "start_date": "2009-06", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-03-20", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00915473" }, { "nct_id": "NCT05345171", "title": "Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "OTC Deficiency" ], "interventions": [ { "name": "DTX301", "type": "GENETIC" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Oral Corticosteroids", "type": "DRUG" }, { "name": "Placebo for oral corticosteroids", "type": "DRUG" }, { "name": "Sodium Acetate", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "OTHER", "DRUG" ], "sponsor": "Ultragenyx Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 37, "start_date": "2022-10-18", "completion_date": "2031-03", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 4, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05345171" }, { "nct_id": "NCT01730872", "title": "Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Allergic Conjunctivitis" ], "interventions": [ { "name": "Prednisolone Sodium Phosphate Ophthalmic Solution 1%", "type": "DRUG" }, { "name": "Tears Naturale II Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ORA, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2012-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2019-06-19", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 1, "location_summary": "Andover, Massachusetts", "locations": [ { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730872" }, { "nct_id": "NCT01639339", "title": "Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lupus Nephritis" ], "interventions": [ { "name": "Placebo plus standard therapy", "type": "BIOLOGICAL" }, { "name": "Belimumab 10 mg/kg plus standard therapy", "type": "BIOLOGICAL" }, { "name": "Standard therapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Human Genome Sciences Inc., a GSK Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 448, "start_date": "2012-07-12", "completion_date": "2020-03-12", "has_results": true, "last_update_posted_date": "2021-03-19", "last_synced_at": "2026-09-29T10:43:03.604Z", "location_count": 17, "location_summary": "La Palma, California • San Leandro, California • Torrance, California + 13 more", "locations": [ { "city": "La Palma", "state": "California" }, { "city": "San Leandro", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01639339" } ] }